DELTA-FLY-PHARMA
150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction (LoDAC, Azacytidine, Decitabine, Venetoclax combo-regimens) or intensive reinduction (high and intermediate dose of Cytarabine regimens) in the 2nd, 3rd, or 4th salvage of AML and the 1st interim analysis of this study shall be done for NDA approval to the FDA in US soon after confirmation of the superiority of DFP-10917 arm. The endpoint is CR rate for primary and the Overall Survival for secondary. DFP-10917 (Radgocitabine) was granted as Orphan Drug Designation (ODD) by the FDA in US.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230427006072/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MN-KLDISCOVERY-INC.2.5.2024 22:31:29 CEST | Press release
KLDiscovery Takes Steps to Strengthen Balance Sheet and Long-Term Financial Foundation
MA-SES-AI2.5.2024 22:16:29 CEST | Press release
SES AI Reports First Quarter 2024 Earnings Results; Affirms 2024 Outlook
IN-IAC2.5.2024 20:01:27 CEST | Press release
The Indy Autonomous Challenge Returns to the Indianapolis Motor Speedway on September 6, 2024
TX-MARY-KAY2.5.2024 19:08:26 CEST | Press release
Mary Kay Inc. Announces Expansion Into Denmark, Strengthening Its Commitment to Women's Empowerment in Scandinavia
CT-INTERACTIVE-BROKERS2.5.2024 16:01:34 CEST | Press release
Interactive Brokers Launches Daily Options on the CAC 40® Index
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom